Fairmount Funds Management LLC, Director, 10% Owner at Viridian Therapeutics, Inc.\DE (VRDN), bought 1,176,470 shares at $17.00 ($20.0M) on 2026-05-11, disclosed to the SEC on 2026-05-13.
Fairmount Funds Management LLC executed a $20 million insider purchase, marking the largest insider transaction in VRDN's history. This move comes as the stock has retraced 40% from its 52-week high, potentially signaling confidence ahead of upcoming regulatory catalysts.
VRDN is currently trading at $17.05, down 2.35% over the last five days but still down 40.7% from its 90-day high. The stock remains 50.28% below its 52-week high of $34.29, having retraced significantly from recent highs.
Key catalysts include an FDA decision expected on June 30 regarding the company's thyroid eye disease drug, and a $350 million upsized public offering announced on May 21. The largest insider purchase in VRDN's history by Fairmount Funds Management on May 11 also serves as a bullish signal.
The stock carries a high short interest of 11.62%, which could exacerbate downside if the June 30 FDA decision disappoints. Additionally, the company is currently trading with a negative forward P/E of -6.77, indicating it is not yet profitable.
Something here stands out, but not much.
| Filing → |
| SYRE | SELL | 2026-06-23 | $399.7M | — | Filing → |
| ZBIO | BUY | 2026-04-01 | $3.0M | — | Filing → |
| COGT | SELL | 2026-03-31 | $242.6M | — | Filing → |